LMT Lombard Med.Tec

 

TIDMLMT 
 
RNS Number : 1844M 
Lombard Medical Technologies PLC 
23 January 2009 
 

Press Information 
 
 
Lombard Medical Technologies PLC 
("Lombard Medical" or "the Company") 
 
 
 
 
Result of Offer to qualifying shareholders and qualifying employees ("Qualifying 
Participants") 
 
 
 
 
 
 
London, UK, 23 January 2009 - On Friday 9 January 2009, the Company announced a 
fund raising that included an offer to Qualifying Participants of up to 
222,311,500 new ordinary shares of 1p each of the Company at a price of 1p per 
share (the "Offer"). 
 
 
The Company is pleased to announce that, at the close of the Offer, Qualifying 
Participants had applied for 23,734,835 new ordinary shares of 1p each at a 
price of 1p per share raising approximately GBP237,000. 
 
 
The Offer was in addition to the placing and subscription, also announced on 9 
January 2009, which conditionally raised GBP6.1 million ("Placing and 
Subscription"). 
 
 
The Offer, together with the Placing and Subscription, are subject to the 
approval of shareholders of the Company at a General Meeting to be held at 
10.00am on Monday 26 January 2009. 
 
 
It is expected that dealings in the 585,234,835 ordinary shares of 1p each 
issued pursuant to the Offer and the Placing and Subscription will commence on 
the AIM market of the London Stock Exchange on Tuesday 27 January 2009. 
 
 
Details of the Offer, the Placing and Subscription were set out in the 
announcement published by the Company on 9 January 2009. 
 
 
 
 
Enquiries: 
+-------------------------------------------------+----------------------------+ 
| Lombard Medical Technologies PLC                |         Tel: 01235 750 800 | 
+-------------------------------------------------+----------------------------+ 
| Simon Neathercoat, Non-executive Chairman       |                            | 
+-------------------------------------------------+----------------------------+ 
| Brian Howlett, Chief Executive Officer          |                            | 
+-------------------------------------------------+----------------------------+ 
| Tim Hall, Finance Director                      |                            | 
+-------------------------------------------------+----------------------------+ 
|                                                 |                            | 
+-------------------------------------------------+----------------------------+ 
| Financial Dynamics                              |         Tel: 020 7831 3113 | 
+-------------------------------------------------+----------------------------+ 
| David Yates / Susan Quigley                     |                            | 
+-------------------------------------------------+----------------------------+ 
|                                                 |                            | 
+-------------------------------------------------+----------------------------+ 
| Nomura Code                                     |         Tel: 020 7776 1200 | 
+-------------------------------------------------+----------------------------+ 
| Juliet Thompson / Richard Potts                 |                            | 
+-------------------------------------------------+----------------------------+ 
 
 
 
 
Notes to editors 
About Lombard Medical 
Lombard Medical Technologies PLC is a medical devices group developing stent 
grafts and other medical products for use in the treatment of vascular disease. 
The Company's lead product, Aorfix(TM), is an endovascular stent graft for the 
treatment of abdominal aortic aneurysms (AAAs), a balloon-like enlargement of 
the aorta which, if untreated, may rupture and cause death. Approximately 1.7 
million people have AAAs in the US where it is the 13th largest cause of death. 
The market for endovascular stent grafts for the treatment of AAA is currently 
worth over $600 million and is expected to grow to around a $1 billion by 2010. 
Aorfix(TM) is currently being commercialised in the EU, with a pivotal clinical 
trial ongoing in the USA. 
 
 
The Company's Polymer Coatings Division has developed a novel hydrophilic 
surface treatment to reduce friction on catheters called GlideMax(TM), which is 
available for licensing, and is using its polymer coating technology in a number 
of research collaborations developing novel products for the $5 billion 
drug-eluting stent market. 
 
 
The Company headquartered in Oxfordshire, with operations in Yorkshire, Ayrshire 
and Boston, USA. 
Further background on the Company can be found at www.lombardmedical.com. 
 
 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 LISCKNKQPBKDQDB 
 

Lombard Medical Technologies (LSE:LMT)
Historical Stock Chart
From Jun 2024 to Jul 2024

Lombard Medical Technologies (LSE:LMT)
Historical Stock Chart
From Jul 2023 to Jul 2024